




# THERAPEUTICS & DIAGNOSTICS

UTU TTO  
Technology & IP  
Available for  
Licensing

## Diagnostic, Prognostic, Therapeutic and Patient Stratification Tools for Cancers


### Therapeutics for the most common & fatal type of brain cancer

- The molecular mechanism of treatment resistance in glioblastoma now revealed as overexpression of PP2A inhibitor PME-1 (*Kaur et al., Cancer Res, Epub 2016*)
- Efficient therapy is accomplished by combining the blocking of **PME-1** and/or **HDAC4** with chemotherapy
- Significant evidence in a xenograft mouse model
- WO2014009609A1, EP2872631B1; WO2014033367A1, EP2890986B1; WO2012175798A2, EP2723450B1, JP6001655B2, US9476050B2



### Prognostic gene variants in aggressive prostate cancer

- Genetic predisposition to aggressive PrCa in Caucasians now traced to two synergistic germline mutations (*ms submitted*)
- Dual carriers of the two **gene variants** have a high risk of developing clinically relevant prostate cancer (OR 23.4) and especially aggressive PrCa such as CRPC (OR 36.6).
- Provides a new tool for patient stratification and for improved personalized care with more informed therapeutic actions
- WO2017203100A1




### Immunostimulatory glycocluster compounds for immunotherapy of cancers

- Used in monotherapy or as adjuvants to stimulate immune response towards malignant cells
- Significantly suppressed the growth of melanoma in a xenograft mouse model
- WO2012175813A1; WO2017109288A1; WO2017207542A1

### Prognostic expression marker for Acute Myeloid Leukemia (AML)

- A novel oncogene variant predicting poor survival in AML (HR 1.51)
- Allows stratification of patients with the poorest prognosis for the most efficient therapies
- Allows differentiation of good risk patients among intermediate risk patients
- Independent of current risk grouping – provides significant added value for personalized therapy
- Priority patent application FI20176032 (public 05/2019)



### Solid cancers Prognostics & Therapy

### Novel immuno-oncological approach

- Efficient elimination of the tumor cell-derived immunosuppressant adenosine
- Invention directly combinable with therapeutic antibodies (e.g. anti-CD73 / anti-CD39)
- Targets aggressive cancers such as melanoma
- Efficacy studies in mouse cancer models (ongoing)
- Priority patent application public 07/2019

### CONTACT INFORMATION

Piia von Lode, PhD  
Innovation Manager  
piia.vonlode@utu.fi

University of Turku  
Innovation Services / UTU TTO  
FI-20014 TURUN YLIOPISTO

utu.fi/tto